Tenderwize
Zurück zur Suche

Medicinal product with the active substance Sevelamer hydrochloride (ATC: V03AE02)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Oct 30, 2026 · 65 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Sevelamer hydrochlorid (ATC: V03AE02)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

20 / 100

Risikofaktoren

No guaranteed purchase volumes; contracts are non-exclusive, so actual revenue depends on market share and prescribing...

Buyer may terminate these contracts if exclusive agreements for the same active substance are awarded during the contra...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for Sevelamer hydrochloride (ATC: V03AE02)
  • Open-house model: anytime accession for all qualified pharmaceutical companies
Vollständige Zusammenfassung anzeigen

Non-exclusive discount agreements ('open-house model') for the pharmaceutical product Sevelamer hydrochloride (ATC: V03AE02) with the AOK Sachsen-Anhalt. Any qualifying pharmaceutical company can join at any time. The contract period is maximum 24 months from January 1, 2025 to December 31, 2026. Estimated contract value is not provided.

Risiken

No guaranteed purchase volumes; contracts are non-exclusive, so actual revenue depends on market share and prescribing...

Buyer may terminate these contracts if exclusive agreements for the same active substance are awarded during the contra...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies

Administrative

  • Must request and submit participation documents fully completed and signed
  • Must comply with the uniform contract terms and conditions

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

Open-house: all qualifying companies get a contract

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Medicinal product with the active substance Sevelamer hydrochloride (ATC: V03AE02)

Conclusion of non-exclusive discount agreements under §130a(8) SGB V for finished medicinal products containing Sevelamer hydrochloride. Open-house model with anytime accession; no exclusivity; contracts can be concluded at any time on identical terms; earliest start 01.01.2025, latest end 31.12.2026.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Zuschlagskriterien

Open-house: all qualifying companies get a contract

Frist

Deadline Oct 30, 2026

Vergabedetails

Veröffentlichungsdatum
12 Nov 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
690399-2024

Dokumente (1)

Ähnliche Ausschreibungen